Shares of Illumina (ILMN), a leading provider of DNA sequencing and array-based technologies, plummeted 5.11% in Tuesday's pre-market trading session. The sharp decline comes in the wake of China's decision to ban imports of genetic sequencers from the U.S. medical equipment maker, as part of its retaliatory measures in the ongoing U.S.-China trade war.

According to recent developments in the trade conflict, China has imposed a series of countermeasures against U.S. businesses. On March 4, Beijing announced export and investment curbs on 25 U.S. firms, citing national security concerns. Notably, Illumina was specifically targeted with a ban on imports of its genetic sequencers, a move that is likely to significantly impact the company's revenue streams in the Chinese market.

This ban is part of a broader set of retaliatory actions by China, which also include 10-15% levies on U.S. agricultural exports, affecting approximately $21 billion worth of U.S. exports. The escalating trade tensions between the world's two largest economies continue to create uncertainty in global markets, with companies like Illumina caught in the crossfire. Investors are closely monitoring the situation, as the ban could potentially lead to a substantial reduction in Illumina's market share in China, one of the world's largest and fastest-growing markets for genetic sequencing technologies.